Self Study Module 1 - MedicalMinute: Case Discussion: Localized HER2-Positive Breast Cancer
Launch Date:
May 25, 2022
May 25, 2022
Primary Audience:
Medical oncologists, Nurses, Nurse Practitioners, Pharmacists
Relevant Terms:
Breast cancer, HER2-positive breast cancer, Brain metastases, CNS metastases
In this module, Dr. Claudine Isaacs discusses various neoadjuvant therapy regimens and how to optimally manage residual disease after neoadjuvant therapy and surgery.
Claudine Isaacs, MD
Professor of Medicine and Oncology
Associate Director for Clinical Research
Georgetown University
Washington, DC
Dr. Claudine Isaacs is a Professor of Medicine and Oncology, Associate Director for Clinical Research and Leader of the Clinical Breast Cancer Program at the Lombardi Comprehensive Cancer Center (LCCC) at Georgetown University. She is also the Medical Director of the Jess and Mildred Fisher Center for Hereditary Cancer and Clinical Genomics Research. She has extensive experience in the conduct of clinical trials focusing on all aspects of breast cancer and currently serves as Co-Chair Endocrine Resistance Working Group of the Translational Breast Cancer Research Consortium (TBCRC) and as Co-Chair of the Clinical Trials Operations Working Group for the I-SPY 2 Trial. She has authored over 200 peer-reviewed publications and edited two textbooks. She has served on a number of national committees including the Scientific Program Committees at ASCO, the ASCO Breast Cancer Guideline Advisory Group, the Breast Oncology Local Diseases Task Force of the Breast Steering Committee of the NCI.1.
Integrate recent advances and available clinical data to optimally sequence HER2-targeted agents in the treatment of HER2-positive breast cancer from early stage through multiple lines of treatment for MBC
